On the other hand, Patel et al. suggested that pleiotropic effects of SGLT2 inhibitors may be independent of glycemic control for cardiovascular diseases, HF and chronic kidney disease with or without T2D [81]. Here, SLC5A2 is linked to chronic kidney disease.